This site is intended for healthcare professionals only
News
Share this article

NICE publishes final guidance on empagliflozin for type 2 diabetes

NICE has published final guidance recommending empagliflozin (Jardiance®, Boehringer Ingelheim) for the treatment of type 2 diabetes.

NICE has published final guidance recommending empagliflozin (Jardiance®, Boehringer Ingelheim) for the treatment of type 2 diabetes.

Empagliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor and has been approved for the following indications:

  • As dual therapy, in combination with metformin, if a sulphonylurea is contraindicated or not tolerated, or if there is significant risk of hypoglycaemia or its consequences.
  • As triple therapy, in combination with metformin and a sulphonylurea  or metformin and a thiazolidinedione.
  • In combination with insulin, with or without other antidiabetes drugs.

The NHS now has a legal obligation to begin funding this treatment for eligible patients within the next 3 months.

The full guidance is available on the NICE website here.

Related content
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.